| scholarly article | Q13442814 |
| P50 | author | Amy D. Klion | Q42870493 |
| P2093 | author name string | G J Gleich | |
| J J Lee | |||
| P F Weller | |||
| P2860 | cites work | Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5) | Q24594391 |
| Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis | Q24629044 | ||
| Search for eosinopenia in hospitalized patients with normal blood leukocyte concentration | Q28304885 | ||
| Reslizumab for Poorly Controlled, Eosinophilic Asthma | Q29040017 | ||
| The eosinophilic leukocyte: structure and function | Q34182912 | ||
| IL-5-induced airway eosinophilia--the key to asthma? | Q34211474 | ||
| T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells | Q34334887 | ||
| Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. | Q34356615 | ||
| Churg-Strauss syndrome: update on recent developments | Q34493888 | ||
| Treatment of patients with the hypereosinophilic syndrome with mepolizumab | Q34762186 | ||
| Eosinophils and atopic dermatitis | Q35775340 | ||
| Schistosoma mansoni infection in eosinophil lineage-ablated mice | Q35849182 | ||
| Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei | Q35974070 | ||
| Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation | Q36032465 | ||
| Recombinant human interleukin 5 is a selective activator of human eosinophil function | Q36354407 | ||
| Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo | Q36369717 | ||
| Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells | Q36509887 | ||
| Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes | Q36573038 | ||
| Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma | Q36654007 | ||
| The hypereosinophilic syndromes: current concepts and treatments | Q37401379 | ||
| Eosinophil deficiency compromises parasite survival in chronic nematode infection. | Q37581970 | ||
| Mepolizumab and exacerbations of refractory eosinophilic asthma | Q37711391 | ||
| Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to Strongyloides stercoralis in mice. | Q38686842 | ||
| A new syndrome characterised by absence of eosinophils and basophils | Q39438215 | ||
| The effect of ablation of eosinophils on immediate-type hypersensitivity reactions | Q39578024 | ||
| Eosinophil ablation and tumor development | Q40776332 | ||
| Disorders of neutrophil function | Q40946706 | ||
| The effect of antiserum to eosinophils and susceptibility and acquired immunity of the guinea-pig to trichostronglyus colubriformis | Q41030414 | ||
| Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma | Q43049820 | ||
| Mepolizumab for prednisone-dependent asthma with sputum eosinophilia | Q46098864 | ||
| Pulmonary biology of anti-interleukin 5 antibodies | Q46436084 | ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 | ||
| A critical role for eosinophils in allergic airways remodeling | Q47925478 | ||
| Defining a link with asthma in mice congenitally deficient in eosinophils. | Q47925494 | ||
| Eosinophils are required for the maintenance of plasma cells in the bone marrow. | Q51024387 | ||
| Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. | Q53564709 | ||
| Reactivity of rabbit antiserum to guinea pig eosinophils | Q67316069 | ||
| Total absence of eosinophils in a patient with chronic urticaria and vitiligo | Q68346142 | ||
| Respiratory burst of normal human eosinophils | Q70175812 | ||
| Circulating eosinophil colony-forming cells in pure eosinophil aplasia | Q70579276 | ||
| Total absence of eosinophils in a patient with an allergic disorder | Q71545083 | ||
| Effects of an antibody to interleukin-5 in a monkey model of asthma | Q71954025 | ||
| Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody | Q72007976 | ||
| A case of chronic aneosinocytosis | Q72106922 | ||
| Acquired basophil and eosinophil deficiency in a patient with hypogammaglobulinaemia associated with thymoma | Q72801950 | ||
| Presentation of case | Q73967632 | ||
| Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys | Q74339887 | ||
| [Primary aneosinophilia] | Q74794426 | ||
| A clinical and experimental study of agammaglobulinemia | Q78692357 | ||
| Aneosinophilia in a patient with bronchial asthma | Q79389032 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 829-835 | |
| P577 | publication date | 2013-06-06 | |
| P1433 | published in | Allergy | Q2699825 |
| P1476 | title | The consequences of not having eosinophils | |
| P478 | volume | 68 |
| Q90262159 | Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma |
| Q59802868 | Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma |
| Q26866943 | Anti-IL5 therapy for asthma and beyond |
| Q41605623 | Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma |
| Q92278515 | Association of the blood eosinophil count with end-organ symptoms |
| Q35565533 | Biologic therapies targeting eosinophils: current status and future prospects |
| Q38394577 | EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders |
| Q55115543 | Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome. |
| Q64113098 | Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
| Q38422236 | Eosinophilic Skin Diseases: A Comprehensive Review |
| Q90348453 | Eosinophils can more than kill |
| Q35898996 | Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis |
| Q57028409 | Impact of eosinophil-peroxidase (EPX) deficiency on eosinophil structure and function in mouse airways |
| Q26825435 | Innate immunity in disease |
| Q28067081 | Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs |
| Q64057019 | Intravital imaging allows real-time characterization of tissue resident eosinophils |
| Q92985120 | Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial |
| Q34544937 | Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience |
| Q92696109 | New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic |
| Q47960048 | Newly divided eosinophils limit ozone-induced airway hyperreactivity in nonsensitized guinea pigs. |
| Q26799600 | Novel Therapies for Eosinophilic Disorders |
| Q38283811 | Novel biomarkers for asthma stratification and personalized therapy |
| Q36297766 | Odd couple: The unexpected partnership of glucocorticoid hormones and cysteinyl-leukotrienes in the extrinsic regulation of murine bone-marrow eosinopoiesis |
| Q26828515 | Re-defining the unique roles for eosinophils in allergic respiratory inflammation |
| Q40208709 | Regulatory Eosinophils Suppress T Cells Partly through Galectin-10. |
| Q38831891 | Role of Eosinophil Granulocytes in Allergic Airway Inflammation Endotypes |
| Q59792091 | Severe refractory asthma: current treatment options and ongoing research |
| Q52719312 | Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. |
| Q90012353 | Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma |
| Q39189229 | Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations. |
| Q92485478 | Targeting eosinophils: severe asthma and beyond |
| Q52571066 | Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. |
| Q52729256 | The Eosinophil: for better or worse, in sickness and in health. |
| Q51483829 | The role of interleukin 5 in asthma. |
| Q38842153 | The safety of monoclonal antibodies in asthma |
| Q38578918 | Treatment of severe asthma: entering the era of targeted therapy |
Search more.